Chemomab Therapeutics Ltd. (CMMB) Financial Analysis & Valuation | Quarter Chart
Chemomab Therapeutics Ltd. (CMMB)
CMMBPrice: $1.81
Fair Value: 🔒
🔒score
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 f... more
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics fo... more
Description
Shares
| Market Cap | $11.14M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Adi Mor George |
| IPO Date | 2019-02-12 | CAGR | — |
| Employees | 20 | Website | www.chemomab.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CMMB chart loading...
Fundamentals
Technicals
| Enterprise Value | $8.01M | P/E Ratio | -1.26 |
| Forward P/E | -56 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.01 |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-1.44 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.95% | ROA | -1.06% |
| ROCE | -1.31% | Current Ratio | 7.42 |
| Quick Ratio | 7.42 | Cash Ratio | 3.81 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -11.44 | Piotroski Score | 3 |